IMDC Model Predicts OS After Second-line Targeted Therapy for mRCC
The International Metastatic Renal Cell Carcinoma Database Consortium model is predictive of patient survival after targeted therapy for mRCC.
The International Metastatic Renal Cell Carcinoma Database Consortium model is predictive of patient survival after targeted therapy for mRCC.
Patients with clear cell RCC and the inherited exonic MET rs11762213 had a worse clinical outcome.
Ipilimumab plus RT vs. RT alone increased median OS in patients with chemotherapy-naïve mCRPC and specific prognostic features.
Trimodal therapy is “appropriate” after transurethral surgery in muscle-invasive bladder urothelial carcinoma not suitable for cystectomy.
Radium-223 dichloride remains an “effective and well-tolerated” treatment for men with CRPC and bone metastases.
Preliminary results from the IMPACT study support the use of targeted PSA screening based on BRCA genotype.
Adding flavopiridol to FOLFOX combination chemotherapy appears to yield tumor responses in some late-relapse refractory germ cell tumors.
Partial and complete responders to bladder-preserving induction chemotherapy for bladder cancer have similar long-term outcomes.
Adding orteronel to prednisone did not improve overall survival in men with metastatic castration-resistant prostate cancer.
Shorter-duration androgen deprivation therapy following radiotherapy is associated with better quality-of-life outcomes in high-risk prostate cancer.